{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:51:39Z","timestamp":1789383099463,"version":"build-2803163510"},"reference-count":53,"publisher":"Frontiers Media SA","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2014.00168","type":"journal-article","created":{"date-parts":[[2014,10,14]],"date-time":"2014-10-14T14:48:17Z","timestamp":1413298097000},"source":"Crossref","is-referenced-by-count":17,"title":["Aldosterone and the Heart: Still an Unresolved Issue?"],"prefix":"10.3389","volume":"5","author":[{"given":"Cristiana","family":"Catena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GianLuca","family":"Colussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Nait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Martinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pezzutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo A.","family":"Sechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2014,10,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1161\/01.CIR.92.2.175","article-title":"Prerequisite for cardiac aldosterone action: mineralocorticoid receptor and 11-\u00ce\u00b2-hydroxysteroid dehydrogenase in the human heart","volume":"92","author":"Lombes","year":"1995","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1042\/CS20070123","article-title":"Aldosterone and end-organ damage","volume":"113","author":"Marney","year":"2007","journal-title":"Clin Sci"},{"key":"B3","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B4","first-page":"893","article-title":"Mineralocorticoid excess, dietary sodium, and myocardial fibrosis","volume":"120","author":"Brilla","year":"1992","journal-title":"J Lab Clin Med"},{"key":"B5","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/hyp.39.2.614","article-title":"Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading","volume":"39","author":"Martinez","year":"2002","journal-title":"Hypertension"},{"key":"B6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1038\/nm.2506","article-title":"Oxidation of CaMKII determines the cardiotoxic effects of aldosterone","volume":"17","author":"He","year":"2011","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1161\/CIRCULATIONAHA.109.915215","article-title":"Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via \u00e2\u20ac\u0153nongenomic\u00e2\u20ac\u009d effects","volume":"122","author":"Mohammed","year":"2010","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"crossref","first-page":"R954","DOI":"10.1152\/ajpregu.00402.2006","article-title":"Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker","volume":"292","author":"Ohtani","year":"2007","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1161\/01.HYP.0000203148.42892.7a","article-title":"Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts","volume":"47","author":"Kobayashi","year":"2006","journal-title":"Hypertension"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1210\/en.2006-1691","article-title":"Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of NADPH oxidase and cardiac remodeling","volume":"148","author":"Stas","year":"2007","journal-title":"Endocrinology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.110.983023","article-title":"Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction","volume":"123","author":"Fraccarollo","year":"2011","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"H1484","DOI":"10.1152\/ajpheart.01000.2010","article-title":"Mineralocorticoid receptor blockade improve diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression","volume":"300","author":"Habibi","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1161\/01.RES.86.1.37","article-title":"Hyperaldosteronemia in rabbits inhibits the sarcolemmal Na(+)-K(+) pump","volume":"86","author":"Mihailidou","year":"2000","journal-title":"Circ Res"},{"key":"B17","first-page":"H2710","article-title":"Aldosterone modulates I(f) current through gene expression in cultured neonatal rat ventricular myocytes","volume":"293","author":"Muto","year":"2007","journal-title":"Am J Physiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1161\/01.CIR.0000039328.33137.6C","article-title":"Increased carotid wall elastic modulus and fibronectin in aldosterone-salt treated rats: effects of eplerenone","volume":"106","author":"Lacolley","year":"2002","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1139\/y05-068","article-title":"CIHR Multidisciplinary Research Group on Hypertension. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy","volume":"83","author":"Neves","year":"2005","journal-title":"Can J Physiol Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jsbmb.2008.03.005","article-title":"Aldosterone and the vascular system","volume":"109","author":"Cachofeiro","year":"2008","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1161\/01.RES.0000159937.05502.d1","article-title":"Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary artery smooth muscle cell","volume":"96","author":"Jaffe","year":"2005","journal-title":"Circ Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1096\/fj.09-147926","article-title":"The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure","volume":"24","author":"Nguyen Dinh Cat","year":"2010","journal-title":"FASEB J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S1734-1140(09)70007-6","article-title":"Effects of aldosterone on coronary function","volume":"61","author":"Benard","year":"2009","journal-title":"Pharmacol Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"H2035","DOI":"10.1152\/ajpheart.00552.2010","article-title":"Coronary endothelial dysfunction after cardiomyocyte \u00e2\u20ac\u201c specific mineralocorticoid receptor overexpression","volume":"300","author":"Favre","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B25","first-page":"85","article-title":"Left ventricular hypertrophy: an independent risk factor","volume":"20","author":"Frohlich","year":"1990","journal-title":"Cardiovasc Clin"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1001\/jama.292.19.2350","article-title":"Prognostic significance of left ventricular mass change during treatment in hypertension","volume":"292","author":"Devereux","year":"2004","journal-title":"JAMA"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1001\/jama.1996.03530430051039","article-title":"Reversal of left ventricular hypertrophy in hypertension: a metaanalysis of randomized double-blind studies","volume":"275","author":"Schmieder","year":"1996","journal-title":"JAMA"},{"key":"B28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/vhrm.2008.04.01.67","article-title":"Angiotensin II receptor blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation prevention","volume":"4","author":"Cuspidi","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"B29","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1677\/joe.0.0910457","article-title":"Rise in plasma concentration of aldosterone during long-term angiotensin II suppression","volume":"91","author":"Staessen","year":"1981","journal-title":"J Endocrinol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/147323000102900103","article-title":"Aldosterone escape during angiotensin-conveting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy","volume":"29","author":"Sato","year":"2001","journal-title":"J Int Med Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1291\/hypres.25.837","article-title":"Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension","volume":"25","author":"Sato","year":"2002","journal-title":"Hypertens Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1253\/circj.70.995","article-title":"Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy","volume":"70","author":"Taniguchi","year":"2006","journal-title":"Circ J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalalpril, and eplerenone\/enelapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"key":"B34","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1161\/01.CIR.0000138680.89536.A9","article-title":"Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure","volume":"110","author":"Mottram","year":"2004","journal-title":"Circulation"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1161\/HYPERTENSIONAHA.109.141531","article-title":"Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study","volume":"55","author":"Gaddam","year":"2010","journal-title":"Hypertension"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1161\/HYPERTENSIONAHA.110.156273","article-title":"Hyperaldosteronism and left ventricular hypertrophy","volume":"56","author":"Sechi","year":"2010","journal-title":"Hypertension"},{"key":"B37","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0002-9610(64)90252-1","article-title":"Clinical characteristics of primary aldosteronism from an analysis of 145 cases","volume":"107","author":"Conn","year":"1964","journal-title":"Am J Surg"},{"key":"B38","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/0002-9343(73)90128-9","article-title":"Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles","volume":"55","author":"Laragh","year":"1973","journal-title":"Am J Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/ajh.2010.169","article-title":"Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment","volume":"23","author":"Sechi","year":"2010","journal-title":"Am J Hypertens"},{"key":"B40","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1055\/s-0031-1291318","article-title":"Aldosterone and the heart: from basic research to clinical evidence","volume":"44","author":"Catena","year":"2012","journal-title":"Horm Metab Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1055\/s-0032-1301902","article-title":"Predictive factors of left ventricular mass changes after treatment of primary aldosteronism","volume":"44","author":"Catena","year":"2012","journal-title":"Horm Metab Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1161\/HYPERTENSIONAHA.108.114140","article-title":"Inappropriate left ventricular mass in patients with primary aldosteronism","volume":"52","author":"Muiesan","year":"2008","journal-title":"Hypertension"},{"key":"B43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1161\/01.HYP.0000023182.68420.EB","article-title":"Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism","volume":"40","author":"Rossi","year":"2002","journal-title":"Hypertension"},{"key":"B44","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1055\/s-0029-1246185","article-title":"Mineralcorticoid antagonists versus surgery in primary aldosteronism","volume":"42","author":"Catena","year":"2010","journal-title":"Horm Metab Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.107.095448","article-title":"Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism","volume":"50","author":"Catena","year":"2007","journal-title":"Hypertension"},{"key":"B46","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1161\/HYPERTENSIONAHA.113.01316","article-title":"Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism","volume":"62","author":"Rossi","year":"2013","journal-title":"Hypertension"},{"key":"B47","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/HJH.0b013e3280108e6f","article-title":"Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study","volume":"25","author":"Giacchetti","year":"2007","journal-title":"J Hypertens"},{"key":"B48","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3275\/7611","article-title":"Cardiovascular changes in patients with primary aldosteronism after surgical or medical treatment","volume":"35","author":"Bernini","year":"2012","journal-title":"J Endocrinol Invest"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1097\/HJH.0000000000000186","article-title":"KCNJ5 gene somatic mutations affect remodelling but do not preclude cure of high blood pressure and regression of left ventricular hypertrophy in primary aldosteronism","volume":"32","author":"Rossi","year":"2014","journal-title":"J Hypertens"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","article-title":"Cardiovascular outcomes in patients with primary aldosteronism after treatment","volume":"168","author":"Catena","year":"2008","journal-title":"Arch Intern Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1210\/jc.2008-2116","article-title":"Participants of the German Conn\u00e2\u20ac\u2122s Registry. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn\u00e2\u20ac\u2122s Registry","volume":"94","author":"Born-Frontsberg","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B53","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1210\/jc.2013-2805","article-title":"Long-term cardio- and cerebro-vascular events in patients with primary aldosteronism","volume":"98","author":"Mulatero","year":"2013","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T05:26:45Z","timestamp":1565933205000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fendo.2014.00168\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,14]]},"references-count":53,"URL":"https:\/\/doi.org\/10.3389\/fendo.2014.00168","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,14]]}}}